Celcuity Inc. (CELC) is a groundbreaking diagnostic company fundamentally redefining the way cancer is treated. The company is precision-focused and aims to use their advanced technology to alter the landscape of cancer therapeutics fundamentally. They are listed on NASDAQ under the ticker symbol "CELC." Their revolutionary and proprietary technology, the CELsignia diagnostic platform, was developed to revolutionize how cancer patients are diagnosed and treated.
Founded in 2012 and headquartered in Minneapolis, Minnesota, Celcuity's primary focus is on discovering new cancer subtypes and enabling pharmaceutical companies to develop targeted therapies for these newly identified subtypes. The company applies its technology to clinical tissue from cancer patients allowing them to characterize the cellular activity driving each patient's cancer which in turn helps in identifying more effective treatment options.
Their mission is to improve the clinical outcomes of cancer patients and increase the effectiveness of cancer drugs by providing biopharmaceutical companies with diagnostic tools and information. The company's cornerstone technology, CELsignia, is the only known diagnostic platform that can analyze live patient cell activity. This ability opens up new avenues for drug development and fundamentally changes the way cancers are classified and treated.
A game-changer in Cancology, CELsignia shifts the diagnostic focus from the genetic mutations, which are common to different cancer types, to the underlying cell behavior causing the disease. This shift allows for a more precise identification of cancer subtypes and their activities, thereby exponentially improving targeted treatment options.
Under the leadership of Brian Sullivan, the Founder, Chairman, and CEO, Celcuity has grown from a start-up biotech firm into a publicly listed company with a diverse portfolio of services and a potential breakthrough technology. Sullivan, who has over three decades of healthcare industry experience, assembled a strong team of cancer biologists and medicinal chemists to deliver on the mission of revolutionizing cancer treatment paradigms.
Celcuity embraces a collaborative approach, working in partnership with third-party biopharmaceutical firms for preclinical and clinical testing of targeted therapies that CESignia diagnostic services have influenced the development of. While still in its early phases, this approach provides Celcuity with tremendous growth potential as their unique diagnostic services become more integrated within the cancer therapeutics market.
In conclusion, the innovative approach of Celcuity Inc. has set new benchmarks in the industry and could significantly improve the survival and recovery chances for cancer patients in the future. The company continues to remain on the cusp of scientific revolution, redefining the future of cancer treatment. Their pioneering work makes them not only leaders in diagnostic advancement but also forerunners in improving the lives of countless individuals affected by cancer around the globe.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Celcuity (CELC), a clinical-stage biotechnology company, is trading at $80.61, which is approximately 50% below its estimated fair value of $161, primarily due to the potential of its drug gedatolisib. The bullish valuation depends on gedatolisib successfully navigating regulatory hurdles and clinical trials, with management projecting peak revenues of $2.5 billion to $3 billion in its addressable market. While the stock has seen a recent pullback, its long-term momentum remains strong, with significant returns over the past three years.
This article analyzes Celcuity Inc. (NASDAQ: CELC) volatility, presenting neutral near and mid-term readings but a positive long-term bias. It outlines institutional trading strategies, including position, momentum breakout, and risk hedging, based on AI models, with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal insights and emphasizes risk management for optimal trading.
Celcuity Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK™ (gedatolisib) to treat HR+/HER2-, PIK3CA mutant locally advanced or metastatic breast cancer. This application is supported by positive Phase 3 VIKTORIA-1 clinical trial results, where REVTORPYK significantly reduced the risk of disease progression or death. If approved, REVTORPYK would be the first therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms and mTOR complexes mTORC1 and mTORC2.
Celcuity Inc. reported significant net losses in Q2 2026, driven by increased spending for the clinical development and potential commercialization of gedatolisib, particularly REVTORPYK. While the FDA approval of REVTORPYK is a positive catalyst, the widening losses highlight a critical risk: whether future revenue can offset the growing cash burn. The article suggests investors need to assess if REVTORPYK's launch and future trial results will outpace the company's financial commitments.
E Fund Management Co. Ltd. has acquired 45,895 shares of Celcuity, Inc. (NASDAQ:CELC), valued at approximately $4.8 million, representing a 0.09% stake in the company. Institutional investors collectively own 63.33% of Celcuity, with several firms adjusting their positions. Despite a recent earnings miss and a stock price below its 52-week high, analysts maintain a "Moderate Buy" consensus rating with an average price target of $154.55.
Celcuity is addressing investor concerns regarding the slower-than-expected launch of its breast cancer drug, Revtorpyk, which led to a significant stock drop. The delay is primarily due to awaiting FDA approval for a second manufacturing facility. Despite this, the company remains confident in the drug's potential, anticipating annual sales exceeding $6 billion, and expects shipments to begin by the end of the third quarter.
Citizens Jmp has reiterated its "Market Outperform" rating for Celcuity (NASDAQ:CELC), setting a price target of $177, which suggests a 92% potential upside. Despite missing quarterly adjusted earnings estimates, analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $153.64, as institutional investors hold a significant stake in the company. Celcuity, a clinical-stage biotechnology company, specializes in precision oncology diagnostics to optimize cancer treatment selection.
Guggenheim raised its price target on Celcuity Inc (NASDAQ:CELC) to $175 from $165, maintaining a Buy rating, citing the higher-than-expected disclosed price of Revtorpyk. Celcuity plans to begin commercial shipments of Revtorpyk in late Q3 and submit a supplemental new drug application for PIK3CAm in Q3 2026. Despite a wider-than-expected loss in Q2 2026, the company holds a strong cash balance and positive analyst outlooks, although some price targets have been adjusted.